Dr. Chan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Amgen Center Drive
Bldg 27, 3E
Thousand Oaks, CA 91320
Summary
- Edward Chan, MD, is a pediatric hematologist/oncologist based in Thousand Oaks, CA. He earned his medical degree from Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in 1997, then completed a pediatrics residency at University at Buffalo and a pediatric hematology/oncology fellowship at Cincinnati Children's Hospital Medical Center. He has held positions at Cincinnati Children's Hospital, Stony Brook University Hospital, and currently works as a Clinical Research Clinical Scientist at Amgen. His experience is in clinical research and pediatric hematology/oncology. He also has numerous publications under his belt, with the majority being in the area of oncology. Additionally, he has been involved in several clinical trials focusing on advanced non-CNS tumors, melanoma, and neuroblastoma.
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 2000 - 2003
University at BuffaloResidency, Pediatrics, 1997 - 2000- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1997
Certifications & Licensure
NY State Medical License 2005 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
- Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma Start of enrollment: 2015 Feb 03
- Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma Start of enrollment: 2014 Dec 08
- Join now to see all
Publications & Presentations
PubMed
- 87 citationsRandomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.Jason A Chesney, Antoni Ribas, Georgina V Long, John M Kirkwood, Reinhard Dummer
Journal of Clinical Oncology. 2023-01-20 - 2 citationsA phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.Konrad Klinghammer, James Keller, Jonathan George, Jens Hoffmann, Edward L. Chan
International Journal of Cancer. 2018-01-01 - 7 citationsA Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.James Keller, Anjaruwee S. Nimnual, Mathew S. Varghese, Kristen A. VanHeyst, Michael J. Hayman
Molecular Cancer Research. 2016-08-01
Grant Support
- Validating the prognostic value of EGFR768 in neuroblastomaNational Cancer Institute2014–2016
- Ron as an adjunct biomarker for EGFR expressing head and neck cancersAmerican Cancer Society2009–2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
